Obesity
Pipeline by Development Stage
Drug Modality Breakdown
Obesity is a $11.6B market in peak growth, driven by GLP-1 and dual-agonist therapies with primary indications in weight management.
Key Trends
- GLP-1 agonists dominate 80% of indication-attributable spending; dual-agonist tirzepatide rapidly expanding
- Novo Nordisk and Eli Lilly control ~79% of market; legacy lipase inhibitors approaching end-of-life
- Patent protection extends to 2038–2041 for blockbusters; minimal generic erosion risk until late 2030s
Career Verdict
Excellent specialization opportunity: explosive demand in commercial, medical affairs, and clinical operations roles, with job growth anchored to two dominant companies through the 2030s.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | WEGOVY (semaglutide) | Novo Nordisk | N/A — attribution incomplete | — | Peak | Growing | 14.7yr |
| 2 | ZEPBOUND (tirzepatide) | Eli Lilly and Company | N/A — attribution incomplete | — | Growth | Growing | 13.2yr |
| 3 | MOUNJARO (tirzepatide) | Eli Lilly and Company | $2.4B | — | Peak | Stable | 15.6yr |
| 4 | XENICAL (orlistat) | GSK | $283K | — | LOE_Approaching | Declining |
Drug Class Breakdown
rapidly expanding in obesity segment
accelerating adoption in obesity-primary formulations
legacy decline
Career Outlook
GrowingObesity specialization is strategically sound through 2038–2041. Two companies (Novo Nordisk, Eli Lilly) control 79% of revenue and will dominate hiring; Novo Nordisk faces patent cliff risk in 2038, likely triggering restructuring and cost-cutting post-2040. Early-career professionals should prioritize Eli Lilly (later cliff, defensive position) or adjacent players (AstraZeneca, Merck) expanding into obesity-metabolic platforms. Experienced professionals should target leadership roles in medical affairs and clinical operations, where GLP-1 expertise commands 40%+ salary premiums.
Breaking In
Target contract research organizations (CROs) or smaller metabolic biotech first to build obesity-specific trial operations experience; then transition to Eli Lilly, Novo Nordisk, or emerging players (Amgen, Viking Therapeutics) where obesity is a strategic priority.
For Experienced Professionals
Leverage 2024–2028 peak market growth to negotiate leadership roles in medical affairs or market access; plan exit strategy or pivot by 2037–2038 to avoid Novo Nordisk restructuring fallout, or double down on Eli Lilly's extended patent runway.
In-Demand Skills
Best For
Hiring Landscape
3,731 total jobs across obesity ecosystem; commercial roles lead (764 jobs, $266K avg), followed by engineering (500 jobs, $225K) and R&D (307 jobs, $190K). AstraZeneca leads hiring (1,213 jobs), suggesting obesity-adjacent metabolic program expansion; GSK retains 564 roles despite legacy portfolio decline. Medical Affairs commands premium salaries ($334K avg), reflecting scientific complexity and key opinion leader engagement demands.
Top Hiring Companies
By Department
Commercial and medical affairs roles offer premium compensation ($266K–$334K); high barrier to entry but strong career acceleration for specialists in metabolic disease.
On Market (15)
Approved therapies currently available
Competitive Landscape
130 companies ranked by most advanced pipeline stage
+100 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 48 trials with date data
Clinical Trials (48)
Total enrollment: 22,336 patients across 48 trials
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
A Study of a Novel Precision Medicine Approach For Obesity
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients
Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects
Phase IV Study of Qsymia in Obese Patients
A Trial Evaluating the Effectiveness of Contrave in Patients Who Have Weight Recidivism Following Bariatric Surgery
Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, After 6 Month Behaviour Modification Program.
Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity
Saxenda in Obesity Services (STRIVE Study)
Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years
Adequacy of Perioperative Cefazolin for Surgery Antibiotic Prophylaxis in Obese Patients
Effectiveness of Orally Dosed Emergency Contraception in Obese Women - LNG
Effectiveness of Orally Dosed Emergency Contraception in Obese Women - UPA
Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery
Efficacy of Corifollitropin Alfa in Obese Women in Terms of Clinical and Molecular Parameters of IVF Success
Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults
Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
CURES: The Effect of Deep Curarisation and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity
Intravenous Ibuprofen for Laparoscopic Bariatric Surgery
Studying the Effects of Phentermine on Eating Behavior
DAWL (Dairy and Weight Loss) Study
Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects
Weight Loss With Exenatide Treatment
The Health Influences of Puberty (HIP) Study
Desflurane or Propofol Anesthesia in Elderly Obese Patients Undergoing Total Knee Replacement
Drug Concentration Analysis of Micafungin in Overweight, Obese, and Extremely Obese Volunteers
Trospium Chloride XR in Obese Female Patients With Overactive Bladder
Studying the Effects of Sibutramine on Eating Behavior
A Randomized Clinical Trial To Study Losartan On Endothelial Dysfunction and Insulin Resistance In Obese Patients
Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT
Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.
Biochemical Markers of Growth Response to Growth Hormone Treatment in Children With Idiopathic Short Stature
Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity
A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.
Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial
Effect of Calcium/Vitamin D Supplementation on Body Weight and Fat Loss.
Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese Adults
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Related Jobs in Metabolic Diseases
Medical Director, Pharmacovigilance
Sr Director, Field Medical Lead (Obesity and Metabolic Programs)
Sr Director, Medical Affairs (Obesity and Metabolic Programs)
Digital Commerce Analysis and Insights Lead 数字化商务分析与洞察负责人
Vice President, Global Obesity Medical Lead
Associate Director, SEC Reporting & Technical Accounting
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.